相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Yun-Jung Choi et al.
ATHEROSCLEROSIS (2012)
Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data
T. P. van Staa et al.
DIABETOLOGIA (2012)
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
G. Musso et al.
DIABETOLOGIA (2012)
Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
Chia-Hsuin Chang et al.
HEPATOLOGY (2012)
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
Markolf Hanefeld et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
Assiamira Ferrara et al.
DIABETES CARE (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
Bertrand Cariou et al.
DIABETES CARE (2011)
High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2011)
Thiazolidinediones and fracture risk in patients with Type 2 diabetes
D. J. Betteridge
DIABETIC MEDICINE (2011)
MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin
Harold E. Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
Ralph A. DeFronzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis
Pantelis A. Sarafidis et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2010)
PPARs: diverse regulators in energy metabolism and metabolic diseases
Yong-Xu Wang
CELL RESEARCH (2010)
Secondary Failure of Metformin Monotherapy in Clinical Practice
Jonathan B. Brown et al.
DIABETES CARE (2010)
Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us?
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2010)
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
R. A. DeFronzo
DIABETOLOGIA (2010)
Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
Pioglitazone Use in Combination with Insulin in the Prospective Pioglitazone Clinical Trial in Macrovascular Events Study (PROactive19)
Bernard Charbonnel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
Renata Belfort et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Mandeep Bajaj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
Bernard Zinman et al.
LANCET (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Impact of peripheral arterial disease in patients with diabetes-Results from PROactive (PROactive 11)
J. A. Dormandy et al.
ATHEROSCLEROSIS (2009)
Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus
Rutger W. van der Meer et al.
CIRCULATION (2009)
Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM
Alfonso Perez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Thiazolidinediones and the liver in humans
Hannele Yki-Jarvinen
CURRENT OPINION IN LIPIDOLOGY (2009)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Ralph A. DeFronzo
DIABETES (2009)
Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes
Yoshimasa Aso et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial
D. K. Coletta et al.
DIABETOLOGIA (2009)
Risk of Fractures with Glitazones A Critical Review of the Evidence to Date
Michael Bodmer et al.
DRUG SAFETY (2009)
Expression of Peroxisome Proliferator-Activated Receptor-γ in Key Neuronal Subsets Regulating Glucose Metabolism and Energy Homeostasis
David A. Sarruf et al.
ENDOCRINOLOGY (2009)
Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes
Steven M. Brunelli et al.
KIDNEY INTERNATIONAL (2009)
Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance
Muhammad A. Abdul-Ghani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Fat and beyond: The diverse biology of PPAR gamma
Peter Tontonoz et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis
Leena Haataja et al.
ENDOCRINE REVIEWS (2008)
PROactive: time for a critical appraisal
D. John Betteridge et al.
EUROPEAN HEART JOURNAL (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease
Christian A. Schneider et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
Selective modulation of promoter recruitment and transcriptional activity of PPARγ
Dorothy D. Sears et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Rosiglitazone decreases albuminuria in type 2 diabetic patients
Y. Miyazaki et al.
KIDNEY INTERNATIONAL (2007)
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
Erland Erdmann et al.
DIABETES CARE (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Hypertriglyceridemia
John D. Brunzell
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M. Bajaj et al.
DIABETOLOGIA (2007)
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress-mediated β-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes
Chang-jiang Huang et al.
DIABETES (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction - Results from the PROactive (PROactive 05) study
Erland Erdmann et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism
Gema Medina-Gomez et al.
PLOS GENETICS (2007)
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone
Jose C. Florez et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke - Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
Robert Wilcox et al.
STROKE (2007)
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Amalia Gastaldelli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population - The Bruneck study
Enzo Bonora et al.
DIABETES CARE (2007)
All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study
S. Nag et al.
DIABETIC MEDICINE (2007)
Peroxisonte proliferator-activated receptor-gamma regulates expression of PDX-1 and NKX6.1 in INS-1 cells
Jacob A. Moibi et al.
DIABETES (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes - A randomized trial
Theodore Mazzone et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
Liliane Michalik et al.
PHARMACOLOGICAL REVIEWS (2006)
Effect of various diuretic treatments on rosiglitazone-induced fluid retention
Janaka Karalliedde et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Protection of the kidney by thiazolidinediones: An assessment from bench to bedside
P. A. Sarafidis et al.
KIDNEY INTERNATIONAL (2006)
The effect of pioglitazone on the liver - Role of adiponectin
Amalia Gastaldelli et al.
DIABETES CARE (2006)
Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance
Maura Agostini et al.
CELL METABOLISM (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Molecular mechanisms of insulin resistance:: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85α -: The two sides of a coin
Boris Draznin
DIABETES (2006)
Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus
Takafumi Majima et al.
ENDOCRINE JOURNAL (2006)
Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes
H Sourij et al.
DIABETES CARE (2006)
PPARγ and human metabolic disease
RK Semple et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review
A Natali et al.
DIABETOLOGIA (2006)
Sorting out the roles of PPARα in energy metabolism and vascular horneostasis
P Lefebvre et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The effect of rosiglitazone on the liver: Decreased gluconeogenesis in patients with type 2 diabetes
A Gastaldelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes
AH Xiang et al.
DIABETES (2006)
Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents
K Morino et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway
CY Lin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study
MK Rutter et al.
DIABETES (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption
YF Guan et al.
NATURE MEDICINE (2005)
Dose-response effect of elevated plasma free fatty acid on insulin signaling
R Belfort et al.
DIABETES (2005)
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial
BH Charbonnel et al.
DIABETIC MEDICINE (2005)
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study
DR Matthews et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects
SR Kashyap et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Rosiglitazone prevents the impairment of human islet function induced by fatty acids:: evidence for a role of PPARγ2 in the modulation of insulin secretion
R Lupi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse
T Imai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach
H Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Peroxisome proliferator-activated receptor α target genes
S Mandard et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients
Y Miyazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes
SR Kashyap et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus:: A double-blind, randomized trial
G Schernthaner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Perspectives in diabetes - Molecular mechanisms of insulin resistance that impact cardiovascular biology
CCL Wang et al.
DIABETES (2004)
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
M Hanefeld et al.
DIABETES CARE (2004)
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
M Bajaj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-γ-deficient mice on a high-fat diet
J Matsui et al.
DIABETES (2004)
Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus
R Rajagopalan et al.
DRUGS & AGING (2004)
Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle
WM He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Thiazolidinedione use, fluid retention, and congestive heart failure - A consensus statement from the American Heart Association and American Diabetes Association
RW Nesto et al.
CIRCULATION (2003)
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes
S Kashyap et al.
DIABETES (2003)
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients
Y Miyazaki et al.
DIABETES (2003)
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes:: Potential role of PGC1 and NRF1
ME Patti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes
K Bouzakri et al.
DIABETES (2003)
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes
M Bajaj et al.
DIABETES (2003)
Metabolic and molecular basis of insulin resistance
M Bajaj et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2003)
The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial
AE Caballero et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2003)
Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α):: Transcriptional coactivator and metabolic regulator
P Puigserver et al.
ENDOCRINE REVIEWS (2003)
A diabetes outcome progression trial (ADOPT)
G Viberti et al.
DIABETES CARE (2002)
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes
M Bajaj et al.
DIABETES (2002)
Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women
TA Buchanan et al.
DIABETES (2002)
WY14,643, a peroxisome proliferator-activated receptor α (PPARα) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice
CJ Chou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease - The San Antonio Heart Study
AJG Hanley et al.
DIABETES CARE (2002)
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
Y Miyazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Evaluation of liver function in type 2 diabetic patients during clinical trials - Evidence that rosiglitazone does not cause hepatic dysfunction
HE Lebovitz et al.
DIABETES CARE (2002)
Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer
Y Barak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes
Y Miyazaki et al.
DIABETES CARE (2002)
Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells
HI Kim et al.
DIABETES (2002)
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
AB Mayerson et al.
DIABETES (2002)
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
Y Miyazaki et al.
DIABETOLOGIA (2001)
Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation
W Pratipanawatr et al.
DIABETES (2001)
The peroxisome proliferator-activated receptor α regulates amino acid metabolism
S Kersten et al.
FASEB JOURNAL (2001)
Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179
M Montagnani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
P Raskin et al.
DIABETES CARE (2001)
β-cell mass dynamics in Zucker diabetic fatty rats -: Rosiglitazone prevents the rise in net cell death
DT Finegood et al.
DIABETES (2001)
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
Y Miyazaki et al.
DIABETES CARE (2001)
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial
R Azziz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Cardiovascular morbidity and mortality associated with the metabolic syndrome
B Isomaa et al.
DIABETES CARE (2001)
Rosiglitazone monotherapy is effective in patients with type 2 diabetes
HE Lebovitz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion
KJ McCarthy et al.
KIDNEY INTERNATIONAL (2000)
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes melitus: A randomized, placebo-controlled study
D Einhorn et al.
CLINICAL THERAPEUTICS (2000)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
E Arioglu et al.
ANNALS OF INTERNAL MEDICINE (2000)
Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients
A Krook et al.
DIABETES (2000)
Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle
K Cusi et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Nuclear hormone receptors and mouse skin homeostasis: Implication of PPAR beta
L Michalik et al.
HORMONE RESEARCH (2000)
Hepatic injury due to troglitazone
AH Malik et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
分享论文
